Good luck to OE Abhi Gowda (KES 2013-20) representing Christ’s, Cambridge in the second round of University Challenge at 8.30pm on BBC2.

It's easy to make fun of basic science. It seems ridiculous to study how cone snails hunt their prey. But actually it led to the discovery of pain medication: a peptide from their venom relieves pain but doesn't paralyze us, as we use a calcium channel differently from fish.💪🧪

We are delighted to share the planned transition of Nucleate's co-President from Oliver Dodd to Michael Retchin.

This really is an utterly nonsensical move that is a net negative for the UK and it’s Science Superpower ambition. ft.com/content/409bcc…

Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student!), this manuscript details our attempts to reimagine the structure of CARs to improve their specificity and efficacy. rdcu.be/c7avS

My annual reminder that NIH and NSF still prevent international students from applying for doctoral and postdoctoral fellowships. I'm glad you're here and I know you've sacrificed a lot to be here. We're proud of you!

Delighted to share our new approach for high fidelity sc genotyping combined with scATAC - called GTAC! Do check it out! We love it. Great collaboration with the Hughes and Davies labs also in the WIMM. Credit to Sven, Asger, Angus and all co-authors. cell.com/cell-stem-cell…

Attend our upcoming exclusive event: DEMO DAY! Apply here to mix with great minds that represent the new age of biotech along with our curated network of mentors, industry experts, and investors. lnkd.in/eU7PEKDh #biotech #startup #innovation

Today in bioRxiv, we describe the varied durability of epigenetic editing in the context of cardiovascular disease target genes (hPCSK9, hANGPTL3, and hAGT). biorxiv.org/content/10.110…

Excited to see our latest review published today in HemaSphere Journal (IF = 12.1)! If you are interested in the latest developments in the field of targeted therapies for Acute Myeloid Leukemia, check it out! Thanks so much to Felix A. Radtke paresh vyas Vyas Lab journals.lww.com/hemasphere/Ful…

How do DNMT3A and TET2 mutant clones impact human haematopoiesis?   Excited to share our new pre-print where we identify the cell-intrinsic and extrinsic consequences of mutations in humans with clonal haematopoiesis: doi.org/10.1101/2023.0…   paresh vyas Sven Turkalj MRC WIMM

How can #BaseEditing improve #CART for blood cancers? Drs. @CarlHJune, Saar Gill, & a team at Penn Medicine developed epitope-edited CD45 CAR T cells that were effective against several hematologic malignancies. 🩸 Science Translational Medicine: bit.ly/3sIFDOT ▶️: bit.ly/3ZxuwVz

Announcing the Nucleate Venture Fellowship + $4M in Nucleate Funding Prizes, together with Pillar VC and BlueYard Capital. APPLY by Jan 1st -bit.ly/3GG2pL5 Checkout our press release on Medium here for more information! link.medium.com/FmIjiCGStFb

Check out our latest paper, published Nature Communications. We show that STING activation induces IL18 secretion and thereby enhances CAR T function. Great collaboration between @CarlHJune lab and James Chen UT Southwestern Medical Center. Penn Medicine Penn Medicine MD Penn Postdoctoral Association nature.com/articles/s4146…

Yellowstone Biosciences launches with £16.5 million to pioneer soluble bispecific TCR-based therapies for cancer dlvr.it/T8WYF3

NEW SPINOUT: Yellowstone Biosciences has launched to pioneer new cancer treatments using advanced T-cell therapies based on research from co-founder & MRC MHU Deputy Director paresh vyas (Vyas Lab) Find out more: bit.ly/3Y36kLP

It's just not right... why does insurance charge people out-of-pocket for a medicine no one would take if they didn't have to? We need to cap these costs for patients and #fixinsurance. Please share and help, Mariah Carey , Jessica Alba, Marshall Mathers, P!nk, Jerome Bettis!

Therapy resistance is a major barrier to curing cancer. However, what if we could leverage cancer resistance mechanisms to strategically install them into cell therapies, enhancing their efficacy, safety, and accessibility? nature.com/articles/s4156…